Pediatric Cannabis Hyperemesis Protocol Increases Capsaicin Use and Lowers Haloperidol Dosing

The rising clinical burden of pediatric cannabis hyperemesis

Cannabis hyperemesis syndrome has emerged as a frequent and costly challenge in pediatric emergency departments, particularly in regions where recreational markets have commercialized [1, 2]. Characterized by cyclic episodes of severe vomiting and abdominal pain, the condition often progresses through distinct prodromal and hyperemetic phases that can lead to severe dehydration and electrolyte imbalances in adolescent patients [3, 4]. Traditional antiemetic regimens, such as ondansetron, frequently fail to provide relief, prompting clinicians to explore alternative therapies including dopamine antagonists and topical capsaicin [5, 6]. However, the lack of standardized treatment protocols often leads to exhaustive diagnostic testing and inconsistent prescribing patterns [6, 4]. A new study now evaluates how the formal implementation of a management algorithm influences medication selection and patient throughput in an academic pediatric setting.

Standardizing the emergency response to cyclic vomiting

Standardizing the clinical response to cannabis hyperemesis syndrome remains a priority as pediatric presentations increase. Researchers conducted a retrospective analysis of adolescent encounters at an academic pediatric emergency department between July 2020 and July 2024 to evaluate clinical outcomes following the implementation of a standardized management algorithm. From an initial pool of 533 screened encounters, the study identified 128 encounters that met the inclusion criteria. These encounters represented 44 unique patients, a figure that underscores the recurrent nature of the condition in the adolescent population and the high rate of recidivism often seen when patients continue cannabis use. The primary objective was to determine how the introduction of a structured protocol influenced clinical decision-making, medication selection, and patient flow within the department. To ensure the findings were robust, the authors employed mixed-effects models (a statistical framework that accounts for both fixed effects, such as the treatment protocol, and random variations, such as individual patient differences) to examine the association between the implementation period and hospital admission rates. This model was adjusted for patient age, sex, and the emergency severity index level (a five-level triage tool used to categorize patients by clinical acuity and resource needs). In addition to admission rates, the study utilized a separate mixed-effects model to analyze the emergency department length of stay, adjusting for total daily arrivals to account for the impact of overall hospital volume on individual patient throughput. By controlling for these variables, the researchers sought to isolate the effect of the management algorithm from external factors such as departmental crowding or patient demographics.

Shifts in pharmacologic management and dosing

The implementation of the standardized management algorithm led to a marked shift in the pharmacologic agents selected for adolescent patients. One of the most significant changes was the increased utilization of topical capsaicin, a transient receptor potential vanilloid 1 agonist that is thought to alleviate symptoms by modulating substance P release in the gut and brain, thereby counteracting the cannabinoid-induced disruption of the thermoregulatory system. Following the introduction of the protocol, capsaicin administration rates increased from 2.7% to 22.2% (P<0.001). Similarly, the use of metoclopramide, a dopamine-2 receptor antagonist commonly used for its prokinetic and antiemetic properties, saw a substantial rise. The researchers found that metoclopramide administration rates increased from 6.8% to 42.6% (P<0.001) after the algorithm was established, suggesting a more uniform approach to first-line antiemetic therapy. While the selection of certain medications changed, the use of haloperidol, a typical antipsychotic often utilized off-label for refractory vomiting, demonstrated a different trend. The frequency of haloperidol administration did not change significantly, moving from 20.3% to 9.3% (P=0.138). However, the protocol had a measurable impact on the quantity of the drug delivered to pediatric patients; the mean dose of haloperidol decreased from 2.7 mg to 1.0 mg (P=0.014) after implementation. This reduction in dosage is clinically relevant for the pediatric population, as lower doses of dopamine antagonists may help mitigate the risk of extrapyramidal side effects (movement disorders such as acute dystonia or akathisia caused by dopamine blockade) while still providing symptomatic relief for the cyclic vomiting and abdominal pain characteristic of the syndrome.

Impact on hospital disposition and throughput

Despite the significant shifts in medication selection and dosing, the implementation of the standardized algorithm did not result in a measurable change in hospital disposition or emergency department efficiency. Using mixed-effects models to account for variables such as age, sex, and emergency severity index level, the researchers found that the adjusted odds of hospital admission did not significantly differ following implementation (adjusted OR: 0.57, 95% CI: 0.17, 1.86). Similarly, when adjusting for total daily arrivals to the emergency department, the length of stay remained statistically unchanged (adjusted beta: -0.01, 95% CI: -0.21, 0.20). These findings suggest that while the protocol successfully standardized the clinical approach to cannabis hyperemesis syndrome, it did not immediately translate into reduced resource utilization or faster patient throughput. The study demonstrates that while the algorithm implementation was associated with increased capsaicin and metoclopramide use, there was no change in admission rates or length of stay. This discrepancy highlights the complexity of managing this syndrome in the pediatric population, where symptom severity and the need for intravenous rehydration may dictate disposition more than the specific antiemetic regimen used. Because this retrospective analysis was limited to a single academic center and a cohort of 44 unique patients, the authors concluded that prospective studies are needed to assess optimal management strategies for cannabis hyperemesis syndrome in children. Such research will be essential to determine if standardized pathways can eventually improve patient-centered outcomes, such as time to symptom resolution or the prevention of return visits, which were not significantly altered in this evaluation.

References

1. Myran DT, Roberts R, Pugliese M, Taljaard M, Tanuseputro P, Pacula RL. Changes in Emergency Department Visits for Cannabis Hyperemesis Syndrome Following Recreational Cannabis Legalization and Subsequent Commercialization in Ontario, Canada. JAMA Network Open. 2022. doi:10.1001/jamanetworkopen.2022.31937

2. Hall W, Lynskey MT. Assessing the public health impacts of legalizing recreational cannabis use: the US experience. World Psychiatry. 2020. doi:10.1002/wps.20735

3. Seabrook JA, Seabrook M, Gilliland J. Cannabis Hyperemesis Syndrome in Youth: Clinical Insights and Public Health Implications. International Journal of Environmental Research and Public Health. 2025. doi:10.3390/ijerph22040633

4. Burden HN, Close E, Yankova L, Loyal J. Just a Band-Aid: The Inadequate Response to Cannabis Use Disorder in Youth. Hospital Pediatrics. 2025. doi:10.1542/hpeds.2025-008804

5. Sabbineni M, Scott WH, Punia K, et al. SAEM GRACE: Dopamine antagonists and topical capsaicin for cannabis hyperemesis syndrome in the emergency department: A systematic review of direct evidence. Academic Emergency Medicine. 2023. doi:10.1111/acem.14770

6. Smith SA, Safwat MA, Piper BJ, Addison MA. Unraveling the Enigma of Cannabinoid Hyperemesis Syndrome: A Narrative Review of Diagnosis and Management. Cureus. 2025. doi:10.7759/cureus.90961